ELTX vs ENLV

Elicio Therapeutics, Inc. vs Enlivex Ltd. — Valuation Comparison 2026

ELTX

Biotechnology
Elicio Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$10.61
Last close
Models
7/13
Active
VS

ENLV

Biotechnology
Enlivex Ltd.
Quality
1.6
out of 10
Value Trap
12
SAFE
Price
$0.76
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ELTX Fair ValueELTX Upside ENLV Fair ValueENLV Upside
Bayesian DCF Intrinsic $2.98 -71.9% $0.20 -73.5%
EROIC Spread Intrinsic $0.39 -51.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.32 -97.0% $4.08 +421.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ELTX vs ENLV — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ELTX vs ENLV — Which Stock Is More Undervalued?

ELTX scores higher with a 4.1/10 quality rating vs ENLV's 1.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Elicio Therapeutics, Inc. (ELTX) and Enlivex Ltd. (ENLV) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ELTX currently trades at $10.61 with a QOC of 4.1/10, while ENLV trades at $0.76 with a QOC of 1.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).